<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113146">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630278</url>
  </required_header>
  <id_info>
    <org_study_id>10/6-O</org_study_id>
    <nct_id>NCT01630278</nct_id>
  </id_info>
  <brief_title>Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)</brief_title>
  <acronym>TRIOCAPI</acronym>
  <official_title>Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Very premature infants with a large ductus, selected by an early echocardiogram, will
      receive either ibuprofen or placebo before 12 hours of life. Follow-up will include repeated
      echocardiograms and cranial ultrasound at 36 hours, 14 days and 36 weeks of postconceptional
      age. The primary outcome will be survival without cerebral palsy at years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year survival without cerebral palsy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASQ (Ages and Stages Questionnaire) score at 2 years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of other prematurity-related morbidities (pulmonary, digestive, neurological, renal)</measure>
    <time_frame>2 years</time_frame>
    <description>To compare the outcome between the large and the small ductus groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of outcome according to the McNamara stage at surgical ligation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">385</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Small ductus</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Large ductus ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Large ductus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life</description>
    <arm_group_label>Large ductus ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life</description>
    <arm_group_label>Large ductus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational less than 28 weeks

          -  Postnatal age less than 12 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique GOURNAY, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Véronique GOURNAY, Professor</last_name>
    <phone>+33 2 40 08 77 84</phone>
    <email>veronique.gournay@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hopsital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geraldine GASCOIN, Doctor</last_name>
      <email>geraldine.gascoin@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Geraldine GASCOIN, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hopsital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BRISSAUD, Doctor</last_name>
      <email>olivier.brissaud@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier BRISSAUD, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier DURRMEYER, Professor</last_name>
      <email>Xavier.Durrmeyer@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier DURRMEYER, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry DEBILLON, Professor</last_name>
      <email>TDebillon@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry DEBILLON, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent STORME, Professor</last_name>
      <email>lstorme@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent STORME, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto SIMEONI, Professor</last_name>
      <email>umberto.simeoni@mail.ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Umberto SIMEONI, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univesity Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles CAMBONIE, Professor</last_name>
      <email>g-cambonie@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles CAMBONIE, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique GOURNAY, Professor</last_name>
      <phone>+33 2 40 08 77 84</phone>
      <email>veronique.gournay@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Véronique GOURNAY, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital (AP-HP Groupe hospitalier)</name>
      <address>
        <city>Paris (Cochin)</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana PATKAI</last_name>
      <email>juliana.patkai@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Juliana PATKAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain BEUCHEE, Doctor</last_name>
      <email>alain.beuchee@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Alain BAUCHEE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie SALIBA, Professor</last_name>
      <email>elie.saliba@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Elie SALIBA, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 7, 2016</lastchanged_date>
  <firstreceived_date>June 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prematurity</keyword>
  <keyword>patent ductus arteriosus</keyword>
  <keyword>ibuprofen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
